Cardiac Science is issued U.S. patent titled "Automatic External Cardioverter/Defibrillator".IRVINE, Calif.--(BUSINESS WIRE)--Jan. 10, 1996--Cardiac Science Inc. (OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. :DFIB) Wednesday announced that the U.S. Patent and Trademark Office has issued its patent titled "Automatic External Cardioverter/Defribillator." The U.S. Patent No. 5,464,574 was issued on Dec. 12, 1995, with 14 claims relating to devices and methods for automatically detecting abnormal heart rhythms through external sensors and administering corrective therapy. The corrective therapy may involve automatic delivery of electrical stimulation or therapeutic drugs, or both. The AECD AECD Automatic external cardioverter-defibrillator A device that monitors cardiac rhythm and automatically defibrillates device is designed to terminate ventricular tachyarrhythmias that are the principal cause of sudden cardiac death Sudden Cardiac Death Definition Sudden cardiac death (SCD) is an unexpected death due to heart problems, which occurs within one hour from the start of any cardiac-related symptoms. SCD is sometimes called cardiac arrest. (SCD ScD [L.] Scien´tiae Doc´tor (Doctor of Science). SCD 1 Sickle cell disease, see there 2 Subacute combined degeneration, see there 3 Sudden cardiac death, see there ) in high-risk heart patients. On Nov. 2, 1995, the company announced it had received approval from the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) to expand its Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II of the Powerheart non-surgical device to 235 patients and five investigation centers with the device operating in the Automatic mode. The device, when approved by the FDA, will be for bedside use in hospitals. There is no Phase III required by the FDA for this device. In addition to the bedside model, Cardiac Science is developing ambulatory devices, one model of which is intended to be fully contained in a lightweight vest worn on the body. Cardiac Science develops non-surgical and non-invasive bedside and ambulatory automatic external cardioverter/defibrillator devices that terminate life-threatening ventricular arrhythmias that lead to SCD, considered to be the leading cause of death in the United States and developed countries. CONTACT: Financial Sciences of America Fran Daniels, 310/278-4413 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion